These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34473271)

  • 21. Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa and
    Zheng D; Bergen PJ; Landersdorfer CB; Hirsch EB
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0144621. PubMed ID: 34807759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance of disk diffusion and broth microdilution for fosfomycin susceptibility testing of multidrug-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa.
    Mojica MF; De La Cadena E; Hernández-Gómez C; Correa A; Appel TM; Pallares CJ; Villegas MV
    J Glob Antimicrob Resist; 2020 Jun; 21():391-395. PubMed ID: 32004722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.
    Araj GF; Jaber FA
    J Med Liban; 2012; 60(3):142-7. PubMed ID: 23198454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection.
    Farrell DJ; Morrissey I; De Rubeis D; Robbins M; Felmingham D
    J Infect; 2003 Feb; 46(2):94-100. PubMed ID: 12634070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Susceptibility of ESBL Escherichia coli and Klebsiella pneumoniae to fosfomycin in the Netherlands and comparison of several testing methods including Etest, MIC test strip, Vitek2, Phoenix and disc diffusion.
    van den Bijllaardt W; Schijffelen MJ; Bosboom RW; Cohen Stuart J; Diederen B; Kampinga G; Le TN; Overdevest I; Stals F; Voorn P; Waar K; Mouton JW; Muller AE
    J Antimicrob Chemother; 2018 Sep; 73(9):2380-2387. PubMed ID: 29982660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model.
    Abbott IJ; van Gorp E; Cottingham H; Macesic N; Wallis SC; Roberts JA; Meletiadis J; Peleg AY
    J Antimicrob Chemother; 2023 Feb; 78(2):397-410. PubMed ID: 36473954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study.
    García-Rodríguez JA; Trujillano Martín I; Baquero F; Cisterna R; Gobernado M; Liñares F; Martín-Luengo F; Piédrola G
    J Chemother; 1997 Dec; 9(6):394-402. PubMed ID: 9491838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
    Albiero J; Mazucheli J; Barros JPDR; Szczerepa MMDA; Nishiyama SAB; Carrara-Marroni FE; Sy S; Fidler M; Sy SKB; Tognim MCB
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012.
    Keepers TR; Gomez M; Celeri C; Krause KM; Biek D; Critchley I
    Infect Dis Ther; 2017 Jun; 6(2):233-243. PubMed ID: 28285420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.
    Zykov IN; Samuelsen Ø; Jakobsen L; Småbrekke L; Andersson DI; Sundsfjord A; Frimodt-Møller N
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibility of Nitrofurantoin and Fosfomycin Against Outpatient Urinary Isolates of Multidrug-Resistant Enterococci over a Period of 10 Years from India.
    Das A; Banerjee T; Anupurba S
    Microb Drug Resist; 2020 Dec; 26(12):1509-1515. PubMed ID: 31794690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model.
    Zhanel GG; Parkinson K; Higgins S; Denisuik A; Adam H; Pitout J; Noreddin A; Karlowsky JA
    Diagn Microbiol Infect Dis; 2017 Jul; 88(3):271-275. PubMed ID: 28483306
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Chavan R; Naphade B; Waykar B; Bhagwat S
    Microb Drug Resist; 2021 May; 27(5):678-684. PubMed ID: 33983854
    [No Abstract]   [Full Text] [Related]  

  • 35. Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.
    Merino-Bohórquez V; Docobo-Pérez F; Sojo J; Morales I; Lupión C; Martín D; Cameán M; Hope W; Pascual Á; Rodríguez-Baño J
    Clin Microbiol Infect; 2018 Nov; 24(11):1177-1183. PubMed ID: 29649596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study.
    Sahni RD; Balaji V; Varghese R; John J; Tansarli GS; Falagas ME
    Future Microbiol; 2013 May; 8(5):675-80. PubMed ID: 23642120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
    Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
    Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Vitro Efficacy of Six Alternative Antibiotics against Multidrug Resistant Escherichia Coli and Klebsiella Pneumoniae from Urinary Tract Infections.
    Chen YT; Ahmad Murad K; Ng LS; Seah JT; Park JJ; Tan TY
    Ann Acad Med Singap; 2016 Jun; 45(6):245-50. PubMed ID: 27412057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae.
    Ballestero-Téllez M; Docobo-Pérez F; Rodríguez-Martínez JM; Conejo MC; Ramos-Guelfo MS; Blázquez J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2017 May; 23(5):325-331. PubMed ID: 28062317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The evaluation of antibiotic susceptibility pattern and associated risk factors of UTI in tertiary care hospital of Peshawar.
    Ahmad S; Ali F; Qureshi SA; Uzma B; Shakeela Q; Sabir MS; Ahmad S; Haq I; Rasheed A; Ahmed S; Farooq M
    Pak J Pharm Sci; 2022 May; 35(3(Special)):897-903. PubMed ID: 35791585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.